Cargando…

Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway

PURPOSE: Ginsenoside Rb1 (Rb1), one of the crucial bioactive constituents in Panax ginseng C. A. Mey., possesses anti-type 2 diabetes mellitus (T2DM) property. Nevertheless, the precise mechanism, particularly the impact of Rb1 on hepatic glycogen production, a crucial process in the advancement of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Mingjie, Zhan, Wenjing, Wang, Lexun, Bei, Weijian, Wang, Weixuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590136/
https://www.ncbi.nlm.nih.gov/pubmed/37867629
http://dx.doi.org/10.2147/DMSO.S431423
_version_ 1785123935715590144
author Liang, Mingjie
Zhan, Wenjing
Wang, Lexun
Bei, Weijian
Wang, Weixuan
author_facet Liang, Mingjie
Zhan, Wenjing
Wang, Lexun
Bei, Weijian
Wang, Weixuan
author_sort Liang, Mingjie
collection PubMed
description PURPOSE: Ginsenoside Rb1 (Rb1), one of the crucial bioactive constituents in Panax ginseng C. A. Mey., possesses anti-type 2 diabetes mellitus (T2DM) property. Nevertheless, the precise mechanism, particularly the impact of Rb1 on hepatic glycogen production, a crucial process in the advancement of T2DM, remains poorly understood. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is responsible for prostaglandin E(2) (PGE(2)) inactivation. A recent study has reported that inhibition of 15-PGDH promoted hepatic glycogen synthesis and improved T2DM. Therefore, herein, we aimed to investigate whether Rb1 ameliorated T2DM through 15-PGDH/PGE(2)-regulated hepatic glycogen synthesis. METHODS: By combining streptozotocin with a high-fat diet, we successfully established a mouse model for T2DM. Afterward, these mice were administered Rb1 or metformin for 8 weeks. An insulin-resistant cell model was established by incubating LO2 cells with palmitic acid. Liver glycogen and PGE(2) levels, the expression levels of 15-PGDH, serine/threonine kinase AKT (AKT), and glycogen synthase kinase 3 beta (GSK3β) were measured. Molecular docking was used to predict the binding affinity between 15-PGDH and Rb1. RESULTS: Rb1 administration increased the phosphorylation levels of AKT and GSK3β to enhance glycogen synthesis in the liver of T2DM mice. Molecular docking indicated that Rb1 had a high affinity for 15-PGDH. Moreover, Rb1 treatment resulted in the suppression of elevated 15-PGDH levels and the elevation of decreased PGE(2) levels in the liver of T2DM mice. Furthermore, in vitro experiments showed that Rb1 administration might enhance glycogen production by modulating the 15-PGDH/PGE(2)/PGE(2) receptor EP4 pathway. CONCLUSION: Our findings indicate that Rb1 may enhance liver glycogen production through a 15-PGDH-dependent pathway to ameliorate T2DM, thereby offering a new explanation for the positive impact of Rb1 on T2DM and supporting its potential as an effective therapeutic approach for T2DM.
format Online
Article
Text
id pubmed-10590136
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105901362023-10-22 Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway Liang, Mingjie Zhan, Wenjing Wang, Lexun Bei, Weijian Wang, Weixuan Diabetes Metab Syndr Obes Original Research PURPOSE: Ginsenoside Rb1 (Rb1), one of the crucial bioactive constituents in Panax ginseng C. A. Mey., possesses anti-type 2 diabetes mellitus (T2DM) property. Nevertheless, the precise mechanism, particularly the impact of Rb1 on hepatic glycogen production, a crucial process in the advancement of T2DM, remains poorly understood. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is responsible for prostaglandin E(2) (PGE(2)) inactivation. A recent study has reported that inhibition of 15-PGDH promoted hepatic glycogen synthesis and improved T2DM. Therefore, herein, we aimed to investigate whether Rb1 ameliorated T2DM through 15-PGDH/PGE(2)-regulated hepatic glycogen synthesis. METHODS: By combining streptozotocin with a high-fat diet, we successfully established a mouse model for T2DM. Afterward, these mice were administered Rb1 or metformin for 8 weeks. An insulin-resistant cell model was established by incubating LO2 cells with palmitic acid. Liver glycogen and PGE(2) levels, the expression levels of 15-PGDH, serine/threonine kinase AKT (AKT), and glycogen synthase kinase 3 beta (GSK3β) were measured. Molecular docking was used to predict the binding affinity between 15-PGDH and Rb1. RESULTS: Rb1 administration increased the phosphorylation levels of AKT and GSK3β to enhance glycogen synthesis in the liver of T2DM mice. Molecular docking indicated that Rb1 had a high affinity for 15-PGDH. Moreover, Rb1 treatment resulted in the suppression of elevated 15-PGDH levels and the elevation of decreased PGE(2) levels in the liver of T2DM mice. Furthermore, in vitro experiments showed that Rb1 administration might enhance glycogen production by modulating the 15-PGDH/PGE(2)/PGE(2) receptor EP4 pathway. CONCLUSION: Our findings indicate that Rb1 may enhance liver glycogen production through a 15-PGDH-dependent pathway to ameliorate T2DM, thereby offering a new explanation for the positive impact of Rb1 on T2DM and supporting its potential as an effective therapeutic approach for T2DM. Dove 2023-10-17 /pmc/articles/PMC10590136/ /pubmed/37867629 http://dx.doi.org/10.2147/DMSO.S431423 Text en © 2023 Liang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liang, Mingjie
Zhan, Wenjing
Wang, Lexun
Bei, Weijian
Wang, Weixuan
Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway
title Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway
title_full Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway
title_fullStr Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway
title_full_unstemmed Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway
title_short Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway
title_sort ginsenoside rb1 promotes hepatic glycogen synthesis to ameliorate t2dm through 15-pgdh/pge(2)/ep4 signaling pathway
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590136/
https://www.ncbi.nlm.nih.gov/pubmed/37867629
http://dx.doi.org/10.2147/DMSO.S431423
work_keys_str_mv AT liangmingjie ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway
AT zhanwenjing ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway
AT wanglexun ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway
AT beiweijian ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway
AT wangweixuan ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway